Skip to content

Long-acting antiretrovirals may improve survival for people with poor adherence

Eric Ross, from Massachusetts General Hospital in Boston, speaking at the ID Week Conference.

Long-acting GSK1265744 and TMC278-LA appear safe and practical in early study

William Spreen of GlaxoSmithKline. Photo by Liz Highleyman, hivandhepatitis.com.

Long-acting integrase inhibitor S/GSK1265744 active against multiple HIV subtypes

Long-acting fusion inhibitor albuvirtide looks promising in early studies